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INTRODUCTION
Rapid cycling syndrome is a bipolar af-
fective disorder, amounting to 10% to 30%
of the bipolar population. It is character-
ized by at least four episodes per year and
rapid shifts between cycles. Patients with
bipolar affective disorder, as well as pa-
tients with rapid cycling syndrome, typi-
cally experience their first major mood
episode during adolescence (1–5).
Recently, gene expression data from post
mortem brains of bipolar patients were
compared with those of healthy controls in
two independent studies (6,7). While post
mortem approaches certainly cannot reveal
cyclic changes of gene expression, these
studies also failed to yield a single overlap-
ping candidate gene for bipolar disease.
Moreover, the lack of an adequate animal
model for bipolar disorder demands novel
experimental approaches.
We hypothesized that cycling alter-
ations of brain functions in bipolar dis-
ease are reflected by systemic physiologi-
cal changes that have a molecular genetic
basis. If true, it should be possible to ob-
tain molecular signatures of manic and
depressed states even outside the brain,
such as in peripheral blood mononuclear
cells (PBMC). While not disease causing,
such gene expression changes in PBMC
may shed light on similar cyclic alter-
ations in brain.
To study quantitative peripheral gene
expression, we specifically refrained
from comparing larger groups of bipolar
patients (who are genetically heteroge-
neous and differ in baseline gene expres-
sion profiles), and aimed instead at
monitoring the gene expression in one
individual, serving always as her own
control, at recurrent stages of the disease.
CASE REPORT
The female patient, born in 1945, had
no prior medical illness and no evidence
of neuropsychiatric illnesses in her family.
In 1991, she became ill with rapid cycling
syndrome and kept a diary over her ill-
ness, used to reconstruct 108 cycles over a
16-year period. The time series suggests
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complex rhythms in periodicity with
mean total cycle lengths of 53 ± 21 d,
switching within hours between manic
(mean 28 ± 14 d) and depressed (mean 
26 ± 14 d) episodes without normal inter-
vals (Supplementary Figure 1). Results of
affective rating scales obtained repeatedly
during depressed and manic episodes,
together with psychopathology, neu-
ropsychological test results, appearance,
autonomic, and physical signs are sum-
marized in Table 1.
In addition to typical affective symp-
toms, the patient has physical and
cognitive signs recurring in an episode-
specific manner. In the first 2 to 3 d of a
manic episode, she is sleepless and
restless; in the following d, she sleeps 3
to 4 h per night. The 2 to 3 d before the
end of manic episodes, she notes a 
‘normalization of sleep’ with non-
interrupted sleep of regular 8 h duration.
The patient eats and drinks excessively
during manic episodes, leading to alter-
nating weight changes (up to 5 kg) be-
tween episodes and hyperhydration,
resulting in significant shifts of hemato-
crit and hemoglobin concentrations.
Three d after the onset of manic epi-
sodes, the patient regularly develops
Table 1. Psychopathology, physical signs and neuropsychological test results (before celecoxib).
Category Depressed episode Manic episode
Psychopathology
Mood dysphoric, despair, anxiety expansive, exuberant, irritable
Drive impaired: increased:
- most of the time in bed - seeking contacts
- social withdrawal - loss of inhibition
- neglected personal hygiene - unnecessary purchases
- reduced self-care - booking of travels
Thought process brooding, difficulty making decisions, slowed logorrhea, distractibility, poor concentration,
thinking racing thoughts
Suicidality passive death wishes joie de vivre (“Lebensfreude”)
Gestures and mimic mask-like face and slow limb movements rich in gestures and facial expression
oculomotoric decreased oculomotoric increased
sad appearing searching for eye contact and attention
withdrawn
Voice low pitched, monotonous high pitched, melodious
Handwriting jittery and slow orthographic mistakes and corrections
Dotting moderately impaired normal
Tapping moderately impaired moderately impaired
HAM-Da range between 31 and 38 range between 3 and 4
BDIb range between 44 and 52 range between 3 and 5
YMRSc range between 1 and 3 range between 21 and 24
PANSSd range between 84 and 92 range between 40 and 41
Autonomic and physical signs





Allergy no allergies susceptibility to allergies
Edema no edema edema on lower extremities
Neuropsychology
Short-term memory mildly impaired mildly impaired
Long-term memory normal normal
Working memory moderately impaired severely impaired
Semantic fluency moderately impaired normal
Executive functions moderately impaired severely impaired
Psychomotor speed moderately impaired moderately impaired
aHamilton Depression Rating Scale.
bBeck Depression Inventory.
cYoung Mania Rating Scale.
dPositive and Negative Syndrome Scale.
5 4 8 |  B E G E M A N N  E T  A L . |  M O L  M E D  1 4 ( 9 - 1 0 ) 5 4 6 - 5 5 2 , S E P T E M B E R - O C T O B E R  2 0 0 8
G E N E  E X P R E S S I O N  I N  R A P I D  C Y C L I N G  S Y N D R O M E
edema in her lower extremities that re-
cover immediately after onset of depres-
sion. Only during manic episodes does
she become susceptible to seasonal aller-
gies (hay fever). This allergic response
is rarely observed during depressed epi-
sodes. Witnesses describe a change of
her voice in the last 2 to 3 d of manic
episodes to raspy and less melodious.
At the end of depressed episodes, her
voice becomes more cheerful and richer
in tonal inflections. The patient is not
aware of these changes. Because there
was an episode-specific susceptibility
to allergens, lymphocyte subpopula-
tions were studied by fluorescence-
activated cell sorting in different epi-
sodes. Subtle shifts between CD4-helper
and CD8-suppressor cells were noted
(Supplementary Figure 2).
The cyclic pattern of the patient’s af-
fective disorder has had a poor response
to pharmacologic treatment over the past
16 years, such as lithium, venlafaxine,
chlorprothixene, citalopram, paroxetine,
carbamazepine, valproic acid, trim-
ipramine, lamotrigine, olanzapine, or
flupentixol, and no response to psy-
chotherapy and hypnosis. Antipsychotic
medication, such as flupentixol, some-
what reduced the severity of symptoms
but not the cyclic behavior of the disor-
der. During the time of all analyses pre-
sented here, the patient was on continu-
ous lamotrigine medication (400 mg),
resulting in comparable serum levels of
4.1–8.9 μg/mL upon repeated controls
(therapeutic range: 2-10 μg/mL). No
other medication was allowed 2 wks be-
fore or during the time of each testing, or
before and during the treatment ap-
proach, reported here, using the cy-
clooxygenase inhibitor celecoxib (Cele-
brex, Pfizer, Karlsruhe, Germany, 2 × 200
mg daily per os).
MATERIALS AND METHODS
Strategy of Episode-Dependent Gene
Shift Detection
A three-tiered approach was used to
identify candidate genes that are ex-
pressed in an episode-specific fashion.
In the first step, eight blood samples for
PBMC isolation (see below) were col-
lected (always at 8:00 a.m. after
overnight fasting conditions) in the ap-
proximate middle of two different con-
secutive depressed and manic episodes
on two consecutive days each. All sam-
ple collection was done well outside the
hay fever season and in complete ab-
sence of allergic symptoms. The screen-
ing identified genes that showed at least
two-fold differences in expression in
manic compared with depressed epi-
sodes, and vice versa. After screening by
microarrays, the data set was submitted
to two bioinformatic processing steps
(see below). The data were normalized
and analyzed to identify and exclude
genes that differed between the two
consecutive days within a particular
episode (arbitrary daily variation). Fur-
ther genes were excluded that were dif-
ferentially expressed within the two de-
pressed or within the two manic
episodes (arbitrary monthly variation).
The expression pattern of the remaining
depressed and manic episode genes was
subsequently compared. Using this ap-
proach, several genes were identified
that showed high expression in de-
pressed and low in manic episodes, and
vice versa. Because the patient never had
periods where she was free of symp-
toms, samples could not be obtained
within an euthymic episode.
Isolation of Peripheral Blood
Mononuclear Cells (PBMC)
PBMC were collected applying the
standard Ficoll-Paque Plus isolation pro-
cedure (Amersham Biosciences, Freiburg,
Germany). RNA was prepared using
Trizol and Qiagen RNAeasy columns
(Qiagen, Hilden, Germany). The RNA




Transcriptome analysis was per-
formed using the GeneChip Human Ge-
nome U133 Plus 2.0 (Affymetrix, Santa
Clara, CA, USA) (8) according to the
published protocols (9). All cDNAs
used for microarrays were one-round
amplified. GeneChip data were ana-
lyzed using the software GCOS version
1.2 (Affymetrix). Detailed data analysis
was performed with R open-source





Genes found to be differentially regu-
lated by DNA microarray analysis were
subsequently validated independently
using qRT-PCR. Cyclic changes in the ex-
pression of these genes were confirmed
further on PBMC of additional blood
samples obtained up to two years after
the initial screen. qRT-PCR was per-
formed with the aid of SYBR Green de-
tection on Applied Biosystems 7500 Fast
System. CT (cycle threshold) values were
standardized to CT values of GAPDH.
Primers are listed in Supplementary
Table 1.
Statistical Analyses
All numerical results are presented as
mean ± SD in the text and mean ± SEM in
the Figures. Statistical analyses (10,11) and
Fast Fourier Transformations (12) were
performed as published using MATLAB
R2007a software. Nonparametric indepen-
dent Mann-Whitney U test (two-tailed)
and Student t test (two-tailed) were calcu-
lated using SPSS 16.0 for Windows.
All supplementary materials are available
online at molmed.org.
RESULTS
A three-tiered approach was employed
to identify genes that were regulated in an
episode-specific fashion (Figure 1A). We
grouped the genes in biological categories
and present their mean expression pattern
over six to ten separate time points during
either depression or mania (Figure 1B–1E).
Notably, the genes involved in
prostaglandin metabolism, PTGDS
(lipocalin-type prostaglandin D syn-
thetase), and AKR1C3 (prostaglandin D2
R E S E A R C H  A R T I C L E
M O L  M E D  1 4 ( 9 - 1 0 ) 5 4 6 - 5 5 2 , S E P T E M B E R - O C T O B E R  2 0 0 8  |  B E G E M A N N  E T  A L . |  5 4 9
11-ketoreductase), showed higher expres-
sion in depressed episodes (Figure 1B).
We also identified two neurodevelop-
mental genes that revealed opposing
gene expression: NRG1 (neuregulin-1)
was expressed higher in manic, SPON2
(spondin-2) in depressed episodes (Fig-
ure 1C). Several other genes, involved in
regulation of the immune system, were
episode-specifically expressed. These in-
clude GZMA (granzyme A) and KLRD1
(killer cell lectin-like receptor subfamily D,
member 1/CD94) with higher expression
in depressed as compared with manic
episodes (Figure 1D). Hemoglobin genes
A and B (HBB and HBA) were higher in
manic, compared with depressed epi-
sodes. This contrasts the hemoglobin
(protein) concentration in whole blood
(insert) showing opposite regulation
(Figure 1E).
As discussed below, the most intriguing
finding was the association of prostaglandin-
synthesizing genes PTGDS (lipocalin-type
prostaglandin D synthetase) and AKR1C3
(prostaglandin D2 11-ketoreductase) with
rapid cycling. We undertook a clinical ex-
periment to explore the relevance of this
observation and to distinguish between a
disease marker and mediator. We offered
to the patient a treatment approach ap-
plying (off-label) the cyclooxygenase in-
hibitor celecoxib (Celebrex, Pfizer, 2 ×
200 mg daily oral).
Treatment with celecoxib was started
with 100 mg and increased by 100 mg
daily to reach the final dose of 400 mg
(2 × 200 mg daily) at d 4. This dose has
been continued for more than 5 months
and is well tolerated. Figure 2 illustrates
the clinical course before and during
celecoxib, including psychopathology
ratings that revealed a significant im-
provement of depressed as well as of
manic symptoms.
DISCUSSION
In our first molecular-genetic ap-
proach to alternating gene expression in
bipolar disorders, we used PBMC of a
woman with 16-year history of an ex-
treme form of rapid cycling, and obtained
an episode-specific gene expression pro-
Figure 1. (A) Strategy of episode-dependent gene shift detection using microchip analy-
sis. A three-step strategy was used to identify candidate genes that are expressed in an
episode-specific fashion: Eight blood samples were collected (always at 8:00 a.m.) in two
consecutive depressed and manic episodes on two consecutive days each. After screen-
ing by microarrays, the data set was submitted to two bioinformatic processing steps.
Genes were subtracted that differed between the two consecutive days within a particu-
lar episode (arbitrary daily variation). Further genes were excluded that were differentially
expressed within the two depressed or within the two manic episodes (arbitrary monthly
variation). The expression pattern of the remaining depressed and manic episode genes
was subsequently compared. (B–E) Episode-specific PBMC gene expression involves differ-
ent groups of genes. Genes found to be differentially expressed by microchip screening
were confirmed by qRT-PCR in all samples. Moreover, blood sampling was extended be-
yond the initial screening period, and regulated genes were again validated more than
one year later. Genes were grouped (B–E) according to biological categories. Each bar
represents mean ± SEM of 6 to 12 determinations from cDNAs obtained from PBMC on
different days in independent manic (n = 6; open bars) and depressed (n = 5; filled bars)
episodes. The chart for hemoglobins contains an insert with hemoglobin (protein) con-
centrations in whole blood (n = 7 samples of independent manic and depressed epi-
sodes, respectively). Mean values were compared using independent Student t test
(two-tailed).
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file on an identical genetic background.
Our strategy was set up to minimize the
risk of identifying false positive genes,
due to daily or monthly variations in
gene expression that are disorder-unre-
lated. The gene expression differences
among episodes are small but signifi-
cant, and would not have been recog-
nized in a pool of patients or in compari-
son with healthy controls, due to
different genetic background and modi-
fiers of gene expression. In principle,
such an approach could be employed as
a screening strategy for genes in any
condition with temporal periodic behav-
ior, such as sleep or seasonal phenom-
ena/disorders.
Follow-up studies on larger numbers
of bipolar patients will have to follow,
to confirm the general disease-relevance
of the identified gene expression shifts.
Specifically, patients with a more typical
age of onset and course of bipolar dis-
ease will have to be screened. An age of
onset of 46 years and cycling over dec-
ades without euthymic episodes, as in
our patient, clearly is an exception (3–5).
The patient’s impairments comprise
psychopathological symptoms in combi-
nation with physical signs and symp-
toms, including the immune system, and
a variety of cognitive domains evident
upon neuropsychological testing. Ac-
cordingly, episode-specific gene expres-
sion involved different biological sys-
tems, such as blood, metabolism,
immune functions, as well as neuronal
genes, confirming rapid cycling as a sys-
temic disorder. Like all association stud-
ies, we can make no claim whether or
not a particular gene expression shift is
a cause or consequence of rapid cycling,
and whether similar gene expression
changes occur in the brain. Moreover, it
is currently unknown whether some of
the observed alterations in gene expres-
sion partly reflect the shifts in immune
cell subsets observed here.
Lamotrigine has been shown to alter
expression of certain genes, such as
GABA-A receptor β3 subunit in rat hip-
pocampal cells (13). During the entire
observation period (analysis and experi-
mental treatment) reported in this
paper, however, the patient was al-
ways on the same dose of lamotrigine
(episode-independent), making an in-
fluence of this pharmacological treat-
ment on the alternating gene expression
shown here very unlikely. No other
medication was used.
Some regulated genes identified in
PBMC are known to be expressed in the
nervous system. For example, NRG1 is a
neuronal growth factor regulating dif-
ferentiation, synaptogenesis, and myeli-
nation of the nervous system (14).
NRG1 also is expressed in activated
monocytes (15). Similarly, SPON2
(spondin, mindin) originally was char-
acterized in zebrafish as a protein in-
volved in outgrowth of hippocampal
Figure 2. Clinical course of psychopathology ratings before and during treatment with the cyclooxygenase inhibitor celecoxib. The
course of the Hamilton Depression Rating Scale (HAM-D) scores, the Young Mania Rating Scale (YMRS) scores, and the Positive and Neg-
ative Syndrome Scale (PANSS) scores, presented in line graphs, show a pronounced cycling pattern. Day 0 denotes start of celecoxib
intake. The magnitude of cyclic changes appears to gradually decrease during treatment. Bar graphs give scores (mean ± SEM) of n = 6
depressed and n = 6 manic episodes (two before and four after onset of treatment each). HAM-D score in depressed and YMRS score
in manic episodes decrease significantly upon treatment. Mean values are compared using independent Student t test (two-tailed).
M = manic episode, D = depressed episode.
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neurons (16). It is expressed abundantly
in lymphoid tissue and involved in in-
flammation (17).
Granzymes A and B (GZMA and
GZMB) and several natural killer cell re-
ceptors were higher in depressed epi-
sodes. We speculate that the observed
episode-specific gene expression con-
tributes to the pathogenesis seen in our
patient, including her allergic diathesis.
In contrast, the elevated globin gene
expression in manic episodes found here
may reflect a physiological counter-
regulation to the relative increase in ex-
tracellular fluid (and decrease in hemo-
globin level) due to massive drinking.
Interestingly, two genes were identi-
fied that are essential for prostaglandin
synthesis, PTGDS and AKR1C3. PTGDS
is preferentially expressed in the central
nervous system and mediates synthesis
of PGD2 from PGH2 (the cyclooxygenase-
mediated product of arachidonic acid),
and AKR1C3 mediates synthesis of
PGF2α from PGD2. PGF2α is a PPARγ an-
tagonist, in contrast to two other PGD2
metabolites that are spontaneously con-
verted from PGJ2: Δ
12-PGJ2 and 15-deoxy-
Δ12,14-PGJ2 that are PPARγ agonists.
Prostaglandin synthesis plays a pivotal
role in metabolic homeostasis, sleep
regulation, adipogenesis, allergic re-
sponse, and inflammation (18–22). Al-
tered levels of prostaglandins have
been detected in different body fluids
in patients with major affective disor-
ders (23–28). Also pharmacological evi-
dence (29–31) suggests that altered
prostaglandin metabolism may lead to
mood disorders. All this is consistent
with episode-specific differential gene
expression of PTGDS and AKR1C3 as
revealed in the present case.
Alterations in inflammatory markers
in serum of bipolar patients, such as cy-
tokines, c-reactive protein and compo-
nents of the complement system, have
been reported previously (32–38). There
might well be an interaction between
the prostaglandin system found to be
episodically regulated here, in the 
described case, and these inflammatory
molecules, also in the CNS (35,39,40).
Intriguingly, altered expression of
PTGDS marks the hibernation cycle, and
accumulation of prostaglandins during
hibernation season has been described in
hibernating animals (18,22). Based on our
molecular data, we speculate that the
rapid cycling syndrome in humans may
reflect an evolutionary ancient behav-
ioral program resembling the hibernation
cycle (with periodic eating, high psy-
chomotor activity and nesting behavior,
alternating with episodes of rest and
sleep) (41,42) that becomes pathologi-
cally re-activated by unknown triggers,
thereby creating rapid cycling.
The gene products involved in
prostaglandin metabolism might give
clues to potential treatment targets, but
to confirm their general relevance in
bipolar disease, more patients will have
to be examined for cycling-associated al-
terations in prostaglandin gene expres-
sion. Nevertheless, the positive result of
the clinical experiment with celecoxib in
our patient, showing considerable atten-
uation of both depressed and manic rat-
ing scores, supports a mediator role of
prostaglandins in rapid cycling. We are
fully aware of the limitation of a case re-
port in comparison to a clinical trial.
However, we note that the 16-year clini-
cal history of our patient has never
shown benefits from any of the many
pharmacological treatments, suggesting
that a potential placebo effect in our ex-
periment would be minor.
Supporting our findings, a recent
proof-of-concept trial in Germany in-
cluding patients with major monopolar
depression found beneficial effects on
mood upon 6-wk add-on treatment with
the cyclooxygenase-2 inhibitor celecoxib.
In contrast to our gene expression-based
“hibernation hypothesis of bipolar dis-
ease,” this trial was based on the hypoth-
esis that inflammatory processes might
be involved in the pathogenesis of de-
pression (43). Following the same inflam-
mation hypothesis of depression, another
small 6-wk study was performed in the
United States of America, exploring the
effect of celecoxib as adjunctive agent in
bipolar depression, also with promising
results (44). Bringing hibernation and
inflammation together, it is intriguing
to speculate that rapid cycling bipolar
disorders are characterized by episodic
self-limiting inflammatory processes
that, unlike other inflammatory condi-
tions in the brain, do not lead to overt
neurodegeneration.
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